Video Experimental Relacionado
Updated: Sep 9, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.6K
Fronteras emergentes en las terapias GLP-1: una base de evidencia completa (2025)
Shikha Patel1, Sarfaraz K Niazi2
1mAbtide Scientific Communications, Ahmedabad 380001, India.
Pharmaceutics
|August 28, 2025
Resumen
Los agonistas de los receptores de péptido 1 similares al glucagón (ARGLP-1) son ahora terapias multi-sistema. Ofrecen beneficios más allá del control de la glucosa, afectando la salud cardiovascular, la obesidad y las enfermedades emergentes.
Área de la Ciencia:
- Farmacología y Endocrinología
- Medicina metabólica y cardiovascular
Sus antecedentes:
- Los agonistas de los receptores de péptido 1 similares al glucagón (ARGLP-1) se desarrollaron inicialmente para la reducción de la glucosa.
- Los AR GLP-1 han demostrado un amplio potencial terapéutico en varios sistemas de órganos.
Objetivo del estudio:
- Revisar los mecanismos de acción de los AR del GLP-1.
- Sintetizar la evidencia sobre las aplicaciones clínicas establecidas y emergentes de los AR del GLP-1.
Principales métodos:
- Búsqueda sistemática de la literatura de las principales bases de datos biomédicas (PubMed, Embase, Cochrane) y registros de ensayos clínicos.
- Incluir estudios desde el inicio hasta mayo de 2025 utilizando vocabulario controlado y términos de texto libre.
Principales resultados:
- Los AR de GLP-1 presentan efectos celulares pleiotrópicos, incluida la mejora de la función mitocondrial y las acciones antiinflamatorias.
- Eficacia comprobada en la diabetes (reducción de la HbA1c), la obesidad (pérdida de peso) y las enfermedades cardiovasculares (reducción de la MACE).
- Aplicaciones emergentes en neurología, dermatología, enfermedades respiratorias, adicción y trastornos autoinmunes.
Conclusiones:
- Los AR de GLP-1 representan un avance terapéutico significativo.
- Estos agentes funcionan como moduladores metabólicos integrales con impacto en varios sistemas.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:06Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
01:28Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K